PICAROS - Acalabrutinib RWE on 1L CLL in Spain

Inclusion Criteria: * Age ≥18 years old at starting acalabrutinib treatment. * Diagnosis of CLL. * Start of acalabrutinib treatment (index date) in treatment-naïve CLL patients or those switching in first-line between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit. Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice. * Informed consent (for alive patients). Exclusion Criteria: * Enrolled in any clinical trial during acalabrutinib treatment. * Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.